| Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial) (NCT05679570) | International University of Health and Welfare | 2022-07-12 |
| PET Image in PAH Patients (NCT05452889) | Stephen Y. Chan | 2022-07-11 |
| Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension (NCT05135000) | Novartis Pharmaceuticals | 2022-06-30 |
| A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist (NCT05427162) | Actelion | 2022-06-21 |
| Efficacy of Triple-Combination Therapy in Severe PAH-CHD (NCT06196801) | Guangdong Provincial People's Hospital | 2022-06-17 |
| Exercise Training in Patients With Pulmonary Arterial Hypertension (NCT05242380) | Saglik Bilimleri Universitesi | 2022-06-10 |
| Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension (NCT05566002) | Chinese Pulmonary Vascular Disease Research Group | 2022-06-01 |
| COMPression of Left Main coRonary artEry in patientS With Pulmonary Arterial Hypertension aSymptomatIc fOr aNgina (NCT05413109) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-05-15 |
| Effect of CS1 in Subjects With Pulmonary Arterial Hypertension (NCT05224531) | Cereno Scientific AB | 2022-05-05 |
| A Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients with Renal Insufficiency and Healthy Subjects (NCT05208814) | Vigonvita Life Sciences | 2022-03-31 |
| National Registry and Cohort Study of Pulmonary Vascular Disease (NCT05368467) | Nanjing First Hospital, Nanjing Medical University | 2022-03-29 |
| A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH) (NCT04791514) | Insmed Incorporated | 2022-03-29 |
| Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) (NCT04811092) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2022-03-18 |
| Safety and Efficacy of Nebulized Nitroglycerin in Pulmonary Arterial Hypertension (NCT07214129) | Mansoura University | 2022-03-01 |
| Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function (NCT05185011) | Vigonvita Life Sciences | 2021-12-16 |
| A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) (NCT05036135) | Aerovate Therapeutics | 2021-12-02 |
| A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) (NCT04896008) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2021-12-01 |
| miRNA and Myokines in Patients With PAH (NCT03905083) | University of Pittsburgh | 2021-12-01 |
| Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study (NCT04884971) | University of Minnesota | 2021-11-03 |
| Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs (NCT04930289) | Paragonix Technologies | 2021-10-15 |
| A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants (NCT04955990) | Actelion | 2021-10-14 |
| Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension (NCT04908397) | Vanderbilt University Medical Center | 2021-09-29 |
| Xenon MRI Pulm Hypertension (NCT04991454) | Bastiaan Driehuys | 2021-09-01 |
| Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5 (NCT05039086) | Brigham and Women's Hospital | 2021-09-01 |
| A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD (NCT04691154) | Liquidia Technologies, Inc. | 2021-08-01 |
| Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and Pediatric Patients With Congenital Heart Disease (NCT06784687) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2021-08-01 |
| Functional Exercise Tests in Patients With Systemic Sclerosis (NCT04650659) | University of Aarhus | 2021-07-27 |
| A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) (NCT04813926) | Bayer | 2021-07-16 |
| A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging (NCT04435782) | Actelion | 2021-07-07 |
| HRV as a Marker of Treatment Response in PAH Arterial Hypertension (NCT04451850) | University of Cincinnati | 2021-06-01 |
| Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution (NCT04903730) | Aerami Therapeutics | 2021-05-24 |
| A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) (NCT04732221) | Merck Sharp & Dohme LLC | 2021-05-19 |
| A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (NCT07218029) | Merck Sharp & Dohme LLC | 2021-05-12 |
| Right Atrial Fibrosis in Pulmonary Hypertension (NCT04663230) | University of Giessen | 2021-04-30 |
| Physical Activity and Various Aspects of Quality of Life in Patients With Pulmonary Arterial Hypertension (Ph-PAH) (NCT06312111) | Centre of Postgraduate Medical Education | 2021-04-22 |
| StratosPHere (Non-interventional Study) (NCT05767918) | Papworth Hospital NHS Foundation Trust | 2021-04-14 |
| Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH (NCT05569655) | Chinese Pulmonary Vascular Disease Research Group | 2021-04-06 |
| Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) (NCT04816604) | Gossamer Bio USA, Inc. | 2021-04-05 |
| Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension (NCT04808830) | Izmir Bakircay University | 2021-03-25 |
| A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE) (NCT04712669) | Altavant Sciences GmbH | 2021-03-15 |
| Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System (NCT04555161) | Aria CV, Inc | 2021-03-15 |
| Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension (NCT04787445) | Mayo Clinic | 2021-03-11 |
| Prognostic Value of the Right Ventricular Function by Portable Ultrasound in Patients With Pulmonary Hypertension. (NCT05343091) | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2021-03-01 |
| Medication Reconciliation in Pulmonary Hypertension (NCT04744584) | Assistance Publique - Hôpitaux de Paris | 2021-02-16 |
| A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) (NCT04576988) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2021-01-25 |
| Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects (NCT04084678) | United Therapeutics | 2021-01-20 |
| Positioning Imatinib for Pulmonary Arterial Hypertension (NCT04416750) | Imperial College London | 2021-01-20 |
| TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH (NCT04280523) | Vanderbilt University Medical Center | 2021-01-05 |
| Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension (NCT04483115) | Vigonvita Life Sciences | 2020-11-16 |
| A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension (NCT04503733) | Gmax Biopharm LLC. | 2020-10-22 |
| A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag (NCT04567602) | Janssen-Cilag S.p.A. | 2020-10-06 |
| Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study (NCT04266197) | Respira Therapeutics, Inc. | 2020-09-25 |
| A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers (NCT04505137) | Gmax Biopharm Australia Pty Ltd. | 2020-09-02 |
| Pulmonary Hypertension Biorepository and Registry (NCT04808596) | University of Kansas Medical Center | 2020-08-10 |
| Anxiety Self-management Intervention for Pulmonary Hypertension (NCT04450862) | University of Sheffield | 2020-08-05 |
| Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension (NCT04528056) | RenJi Hospital | 2020-08-01 |
| Implantable System for Remodulin Post-Approval Study (NCT03833323) | Medtronic Cardiac Rhythm and Heart Failure | 2020-08-01 |
| Pulmonary Hypertension Modality of Death and Validation of REVEAL Risk Score (NCT04677608) | iPHNET (italian Pulmonary Hypertension NETwork) | 2020-07-21 |
| Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension (NCT04489251) | Medical College of Wisconsin | 2020-07-01 |
| Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test (NCT03893500) | Stanford University | 2020-07-01 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (NCT04278404) | Duke University | 2020-03-05 |
| Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension (NCT04309838) | University Medicine Greifswald | 2020-03-01 |
| Home-based Exercise Training in Patients With Pulmonary Arterial Hypertension: Effect on Skeletal Muscular Function and Metabolism (NCT04241497) | Laval University | 2020-03-01 |
| Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH) (NCT03838445) | V-Wave Ltd | 2020-02-14 |
| Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension (NCT03926793) | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | 2020-02-04 |
| Olaparib for PAH: a Multicenter Clinical Trial (NCT03782818) | Laval University | 2019-11-20 |
| Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study (NCT04090866) | University of Wisconsin, Madison | 2019-11-14 |
| Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil (NCT03884465) | Liquidia Technologies, Inc. | 2019-11-11 |
| Exercise Capacity Respiratory Muscle Strength Dyspnea and Physical Activity in Pediatric Pulmonary Arterial Hypertension (NCT05124015) | Gazi University | 2019-11-10 |
| Oral CXA-10 in Pulmonary Arterial Hypertension (NCT04125745) | Gladwin, Mark, MD | 2019-10-31 |
| A nUtrition and Lifestyle Intervention in Patients With Pulmonary Arterial HypertensIon (NCT05318950) | Amsterdam UMC, location VUmc | 2019-10-20 |
| A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension (NCT03683186) | United Therapeutics | 2019-09-23 |
| Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study (NCT03655704) | Steeve Provencher | 2019-08-22 |
| A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1) (NCT03924154) | Altavant Sciences GmbH | 2019-08-01 |
| A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension (NCT05343637) | Respira Therapeutics, Inc. | 2019-07-30 |
| Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs (NCT03863990) | Bayer | 2019-07-15 |
| Safety and Efficacy of BIA 5-1058 in PAH (NCT06009185) | Bial - Portela C S.A. | 2019-06-26 |
| DNA Methylation Dynamics Underlying Arterial Remodeling in PAH Patients: CLEOPAHTRA Clinical Trial (NCT04282434) | University of Campania Luigi Vanvitelli | 2019-06-14 |
| Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat) (NCT04316143) | Bial - Portela C S.A. | 2019-06-03 |
| BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension (NCT04086537) | Heidelberg University | 2019-05-02 |
| Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension (NCT03554291) | University of Washington | 2019-05-01 |
| A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (NCT03738150) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2019-04-19 |
| Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (NCT03795428) | PhaseBio Pharmaceuticals Inc. | 2019-04-10 |
| The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia (NCT04207593) | Heidelberg University | 2019-04-01 |
| Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH (NCT04062565) | University of Arizona | 2019-03-25 |
| Subcutaneous Elafin in Healthy Subjects (NCT03522935) | Roham T. Zamanian | 2019-03-18 |
| Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension (NCT03789643) | Akros Pharma Inc. | 2019-03-01 |
| Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise (NCT03718780) | Centre Hospitalier Metropole Savoie | 2019-02-22 |
| EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension (NCT03497689) | United Therapeutics | 2019-01-31 |
| A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (NCT03626688) | United Therapeutics | 2019-01-24 |
| A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002) (NCT03744637) | Merck Sharp & Dohme LLC | 2019-01-18 |
| Algorithms to Diagnose Pulmonary Arterial Hypertension (NCT05417373) | RenJi Hospital | 2019-01-17 |
| Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension (NCT03810443) | Assistance Publique - Hôpitaux de Paris | 2019-01-14 |
| Central China Congenital Heart Disease Associated Pulmonary Arterial Hypertension Cohort Study (NCT03977428) | Wuhan Asia Heart Hospital | 2019-01-01 |
| Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (NCT05437224) | RenJi Hospital | 2018-12-18 |
| A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension (NCT03657095) | Lung Biotechnology PBC | 2018-12-10 |
| Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606 (NCT04041648) | Pharmosa Biopharm Inc. | 2018-11-09 |
| Olaparib for PAH: a Pilot Study (NCT03251872) | Laval University | 2018-10-25 |
| Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension (NCT03528902) | Vanderbilt University Medical Center | 2018-10-01 |
| Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric (NCT03602781) | Bellerophon Pulse Technologies | 2018-08-01 |